Compare BLCO & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | APGE |
|---|---|---|
| Founded | 1853 | 2022 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.7B |
| IPO Year | 2022 | 2023 |
| Metric | BLCO | APGE |
|---|---|---|
| Price | $16.25 | $133.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $18.45 | ★ $109.67 |
| AVG Volume (30 Days) | 344.9K | ★ 5.4M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,101,000,000.00 | N/A |
| Revenue This Year | $8.65 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $13.09 | $34.34 |
| 52 Week High | $18.92 | $133.87 |
| Indicator | BLCO | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 81.20 |
| Support Level | $15.36 | $73.70 |
| Resistance Level | $16.54 | N/A |
| Average True Range (ATR) | 0.48 | 0.44 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 52.59 | 78.87 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.